TransCode Therapeutics (RNAZ) Reports Further Restructuring Jan 12, 2024 04:05PM
TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO Jan 12, 2024 04:05PM
TransCode Therapeutics (RNAZ) Publishes Open Letter to Shareholders, Proposed Reverse Split Jan 4, 2024 08:06AM
TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and Objectives Jan 4, 2024 08:05AM